Many people with moderate or severe pulmonary sarcoidosis — the target market for the investigational therapy efzofitimod — are highly burdened by the disease and are dependent on corticosteroids that […] The post Presentations highlight efzofitimod’s potential for pulmonary sarcoidosis appeared first on Sarcoidosis News.
